Valneva SE (VALN) Interest Expenses (2020 - 2026)
Valneva SE (VALN) posted Interest Expenses of -$6.0 million for Q1 2026, down 120.82% sequentially from $28.6 million in Q4 2025, and up 5.21% YoY from -$5.7 million in Q1 2025.
Valneva SE (VALN) Interest Expenses (2020 - 2026) Analysis & Trends
Valneva SE has reported Interest Expenses for 7 years, with the latest figure at -$6.0 million in Q1 2026.
- Quarterly Interest Expenses rose 5.21% year-over-year to -$6.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $50.1 million (up 93.34% YoY) and the FY2025 annual result came in at $48.8 million, up 87.76% from the prior year.
- Interest Expenses declined to -$6.0 million in Q1 2026 per VALN's latest filing, from $28.6 million in the prior quarter.
- Over five years, Interest Expenses peaked at $5.8 billion in Q3 2023 and troughed at -$5.8 billion in Q2 2023.
- A 5-year average of $6.5 million and a median of -$3.7 million in 2022 frame the typical range for Interest Expenses.
- The widest YoY moves for Interest Expenses: up 111145.84% in 2023, down 156679.69% in 2023.
- Over 5 years, Interest Expenses stood at $33.1 million in 2022, then grew by 4.29% to $34.5 million in 2023, then sank by 80.5% to $6.7 million in 2024, then surged by 325.35% to $28.6 million in 2025, then tumbled by 120.82% to -$6.0 million in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered -$6.0 million, $28.6 million, and $33.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Valneva SE | 618.67 Mn | 477.41 Mn | 1.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.96 Mn |
| Mar 31, 2026 | -5.96 Mn |
| Dec 31, 2025 | 28.64 Mn |
| Dec 31, 2025 | 28.64 Mn |
| Sep 30, 2025 | 33.77 Mn |
| Sep 30, 2025 | 33.77 Mn |
| Jun 30, 2025 | -6.35 Mn |
| Jun 30, 2025 | -6.35 Mn |
| Mar 31, 2025 | -6.29 Mn |
| Mar 31, 2025 | -6.29 Mn |
| Dec 31, 2024 | 6.73 Mn |
| Dec 31, 2024 | 6.73 Mn |
| Sep 30, 2024 | 6.28 Mn |
| Sep 30, 2024 | 6.28 Mn |
| Jun 30, 2024 | 19.19 Mn |
| Jun 30, 2024 | 19.19 Mn |
| Mar 31, 2024 | -7.65 Mn |
| Mar 31, 2024 | -7.65 Mn |
| Dec 31, 2023 | 34.53 Mn |
| Dec 31, 2023 | 34.53 Mn |